Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant nivolumab versus nivolumab + ipilimumab after salvage surgery in high-risk recurrent head and neck squamous cell carcinoma
2017-001277-17Phase 2Active
- Sponsor
- Gustave Roussy
- Start
- Jan 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of nivolumab and ipilimumab in head and neck squamous cell carcinoma (HNSCC) and head and neck cancer (HNC) (2 arms), sponsored by Gustave Roussy. Primary endpoint: Two-year disease-free survival. Started Jan 2018; status: active.
02
Drugs
nivolumabipilimumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)head and neck cancer (HNC)
Beyond the preview
Go deeper on 2017-001277-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001277-17.